The Regulatory Week in Review: April 1, 2016
IN THE NEWS
- The U.S. and China issued a joint statement in which they pledged to sign the Paris Climate Agreement on Earth Day, April 22—an announcement that the White House called a “critical milestone” for two of the world’s biggest polluters that together account for nearly 40 percent of global emissions, and that was intended to spur other countries into signing the Agreement, which must be signed by 55 countries with 55 percent of global emissions in order to be entered into force.
- The Federal Trade Commission (FCC) voted 3-2 along party lines to add Internet services to Lifeline—a program that provides federal subsidies to help defray the costs of communications services for low-income Americans—which the White House and other Lifeline supporters praised as an important step toward increasing Internet access, which many view as a necessary link to education and basic communication, but which its critics have denounced for being a “fiscally irresponsible program” in light of its lack of a firm budget and for not requiring that program participants make a contribution to the cost of service, among other alleged deficiencies.
- The U.S. Food and Drug Administration (FDA) issued eased guidelines for mifepristone, a pill that ends early pregnancy, by decreasing the number of doctor’s appointments required for women taking the pill from three to two, and allowing women to take the pill further into their pregnancies—a change that abortion rights advocates are calling a victory, and which they assert simply reflects what is already standard medical practice in most states, but which anti-abortion groups have railed against as a politicized move that fails to address what they point to as the drug’s adverse effects, including possible illness and even death.
- Eleven environmental and other groups commenced an action in the U.S. District Court for the Northern District of California against the U.S. Food and Drug Administration (FDA), requesting that the court invalidate the agency’s ruling that permits the company, AquaBounty Technologies, to produce genetically engineered salmon, because of what they argue is the FDA’s lack of authority over genetically engineered animals, and because the agency allegedly omitted environmental and other types of risks when it reviewed the company’s application.
WHAT WE’RE READING THIS WEEK
- The Competitive Enterprise Institute sent a letter to Congress urging for a regulatory budget. The Institute argued that a regulatory budget would increase economic growth and reduce the impact of “excessive regulation” on low-income families. Additionally, it advocated for retrospective review every ten years and a requirement that Congress authorize all “major regulations” before they can be implemented.
- A recent U.S. Government Accountability Office (GAO) report examined the U.S. Environmental Protection Agency’s (EPA) oversight of underground drinking water, which the EPA is required to monitor to ensure it has not been contaminated by oil and gas production wastewater. The GAO report concluded that the EPA should request more particular data and provide additional guidance, among other recommendations, given the EPA’s current lack of uniformity in its monitoring and data collection.